Quotes with Resistance & Support
Market Information

Patent dispute resolution, a booster for Ranbaxy

This article was posted on Mar 16, 2010 and is filed under Market News

Ranbaxy Laboratories has firmed up after settling a patent dispute with Takeda Pharmaceutical Company regarding a generic version of the Japanese company’s diabetes drug, Actos, in the United States. India’s leading drug maker by sale is trading at the day’s high of Rs 473, stronger by Rs 7 or 1.7%, on the BSE. The shares had opened at Rs 470 and have touched a low of Rs 467 thus far.

“Under the terms of the agreement, Takeda granted Ranbaxy a non-exclusive royalty-free licence to its US patents covering Actos,” Ranbaxy said in a statement.

The agreement allows Ranbaxy to market a low-cost version of Actos in the US starting from August 17, 2012 – almost 19 months after the basic patent over Actos expires in the US on January 17, 2011.

Ranbaxy has preferred the low risk patent settlement route ever since Daiichi Sankyo, the Japanese drug multinational, picked up a majority stake in the company.

source: Business Standard

Similar Posts:

Breakouts

+ve 30 DMA    50 DMA    150 DMA    200 DMA
-ve 30 DMA    50 DMA    150 DMA    200 DMA

Latest Query

Samrudhiglobal.com wishing you and your friends and family Advance xmas and Happy New year...view more »
- by Sam
Status: Awaiting reply

Market Stats

Search Our Archives

Latest Investment Idea

Recent Comments